Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors

A pharmaceutical composition comprising a compound of formula:

• or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier.

A pharmaceutical composition comprising a compound of formula:

• and a pharmaceutically-acceptable carrier.

A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a crystalline form of the compound of formula:

• wherein the crystalline form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks at 2θ values of 9.67±0.20, 11.61±0.20, 17.61±0.20, 18.88±0.20, and 23.33±0.20.